UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

Annals of oncology, 2014-08, Vol.25 (8), p.1475-1484

2014

Volltextzugriff (PDF)

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

The New England journal of medicine, 2020-11, Vol.383 (21), p.2018-2029

2020

Volltextzugriff (PDF)

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

The New England journal of medicine, 2024-10, Vol.391 (16), p.1486-1498

2024

Volltextzugriff (PDF)

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Annals of oncology, 2011-07, Vol.22 (7), p.1507-1519

2011

Volltextzugriff (PDF)

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

The European respiratory journal, 2012-01, Vol.39 (1), p.172-179

2012

Volltextzugriff (PDF)

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer

Journal of thoracic oncology, 2018-01, Vol.13 (1), p.27-45

2018

Volltextzugriff (PDF)

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

The New England journal of medicine, 2021-06, Vol.384 (25), p.2371-2381

2021

Volltextzugriff (PDF)

Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?

Annals of oncology, 2014-07, Vol.25 (7), p.1283-1293

2014

Volltextzugriff (PDF)

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer

The Journal of experimental medicine, 2019-04, Vol.216 (4), p.982-1000

2019

Volltextzugriff (PDF)

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Annals of oncology, 2014-01, Vol.25 (1), p.126-131

2014

Volltextzugriff (PDF)

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Annals of oncology, 2019-08, Vol.30 (8), p.1321-1328

2019

Volltextzugriff (PDF)

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

The New England journal of medicine, 2020-08, Vol.383 (9), p.813-824

2020

Volltextzugriff (PDF)

Are liquid biopsies a surrogate for tissue EGFR testing?

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i38-i46

2018

Volltextzugriff (PDF)

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

Annals of oncology, 2017-11, Vol.28 (11), p.2715-2724

2017

Volltextzugriff (PDF)

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

The Journal of clinical investigation, 2019-03, Vol.129 (3), p.1211-1228

2019

Volltextzugriff (PDF)

APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613

Clinical lung cancer, 2017-09, Vol.18 (5), p.583-588

2017

Volltextzugriff (PDF)

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

Annals of oncology, 2017-04, Vol.28 (4), p.784-790

2017

Volltextzugriff (PDF)

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Annals of oncology, 2021-05, Vol.32 (5), p.620-630

2021

Volltextzugriff (PDF)

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Clinical cancer research, 2016-12, Vol.22 (24), p.5983-5991

2016

Volltextzugriff (PDF)

Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?

Nature reviews. Clinical oncology, 2022-01, Vol.19 (1), p.7-8

2022

Volltextzugriff (PDF)

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Annals of oncology, 2013-01, Vol.24 (1), p.20-30

2013

Volltextzugriff (PDF)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

Clinical cancer research, 2021-08, Vol.27 (15), p.4160-4167

2021

Volltextzugriff (PDF)

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Future oncology (London, England), 2022-02, Vol.18 (6), p.639-647

2022

Volltextzugriff (PDF)

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Annals of oncology, 2015-07, Vol.26 (7), p.1408-1415

2015

Volltextzugriff (PDF)

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Annals of oncology, 2023-05, Vol.34 (5), p.468-476

2023

Volltextzugriff (PDF)

1 – 25 von 96

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect

ThemaCarcinoma, Non-Small-Cell Lung - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(74)

Publikationsform

Artikel
(96)

Sprache

Englisch
(85)
Französisch
(11)

Erscheinungsjahr

n.n

Thema

Humans
(96)
Life Sciences & Biomedicine
(91)
Science & Technology
(91)
Lung Neoplasms - Drug Therapy
(83)
Oncology
(83)
Carcinoma, Non-Small-Cell Lung - Pathology
(48)
Lung Neoplasms - Pathology
(46)
Male
(45)
Female
(44)
Carcinoma, Non-Small-Cell Lung - Genetics
(41)
Lung Neoplasms - Genetics
(39)
Middle Aged
(39)
Aged
(35)
Adult
(32)
Lung Cancer
(23)
Aged, 80 And Over
(21)
Protein Kinase Inhibitors - Therapeutic Use
(21)
Carcinoma, Non-Small-Cell Lung - Mortality
(20)
Mutation
(20)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010

Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3

Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs?

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Are liquid biopsies a surrogate for tissue EGFR testing?

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer

APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients. EORTC 1613

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers

Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Aktive Filter

Suchergebnisse filtern